This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q73454634
rdf:type
wikibase:Item
schema:description
1954 թվականի ապրիլի 1-ին հրատարակված գիտական հոդված scientific article published on 01 April 1954 artículu científicu espublizáu n'abril de 1954 наукова стаття, опублікована у квітні 1954 im April 1954 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel
p:P577
wds:Q73454634-395C38AA-B646-4097-B116-5A1F608C2FF7
wdt:P577
1954-04-01T00:00:00Z
p:P407
wds:Q73454634-18D09E26-B891-4D05-96E7-9A06823DF73C
wdt:P407
wd:Q1860
p:P2093
wds:Q73454634-A7C321F6-F750-4812-A2D2-10E30CD35699
wdt:P2093
W H MORRISON
rdfs:label
Stability of aqueous solutions commonly employed in the treatment of primary glaucoma. II. Drug passage Stability of aqueous solutions commonly employed in the treatment of primary glaucoma. II. Drug passage
skos:prefLabel
Stability of aqueous solutions commonly employed in the treatment of primary glaucoma. II. Drug passage Stability of aqueous solutions commonly employed in the treatment of primary glaucoma. II. Drug passage
schema:name
Stability of aqueous solutions commonly employed in the treatment of primary glaucoma. II. Drug passage Stability of aqueous solutions commonly employed in the treatment of primary glaucoma. II. Drug passage
p:P1476
wds:Q73454634-64E4DBDA-3250-4F16-98B4-7C5C9E77968D
wdt:P1476
Stability of aqueous solutions commonly employed in the treatment of primary glaucoma. II. Drug passage
p:P304
wds:Q73454634-F1763707-DE77-4F14-B0A1-41EF00DA216F
wdt:P304
557-68; contd
p:P31
wds:Q73454634-DF2B9057-7B9C-4B2D-981A-20D82C863702
wdt:P31
wd:Q13442814
p:P698
wds:Q73454634-AA26F44D-5C5A-480C-B71B-358C308491A2
wdtn:P698
n11:13148286
wdt:P698
13148286
p:P1433
wds:Q73454634-FBE174D5-B248-44A3-B2FC-A6AC5C0DFE8E
wdt:P1433
wd:Q4744258
p:P433
wds:Q73454634-63D51603-4E87-4DD3-B5A5-7C4505A6E050
p:P478
wds:Q73454634-64103F2F-ED6E-4C49-8A95-C09E67E8BB45
wdt:P433
4
wdt:P478
37